Navigation Links
Craniofix Titanium Burr Hole Clamp

ProductsCraniofix Titanium Burr Hole Clamp
Company AESCULAP
Item Craniofix Titanium Burr Hole Clamp
Features Fits securely into the cranial burr hole. Specially designed disks allow for drainage. Curvature of lower disk seats into burr hole. Fast and easy application. Provides optimal stability. Reliable fixation of the bone flap.
Description A unique system for secure fixation of the cranial bone flap after craniotomy. Craniofix eliminates the need for mini plates, screws, and additional drills.
Info AESCULAP
Customer Service: (800) 282-9000
Web site: http://www.aesculapusa.com/

Related medicine products :

1. Craniofix Titanium Clamp
2. Hydroview Insertion Forceps - Titanium
3. Titanium Bayonet Forceps
4. Titanium Foot Activated Forceps
5. Lorenz 1.0 mm Titanium System
6. Lorenz 2.0 mm Flexible Titanium
7. Lorenz 1.5 mm Titanium System
8. Lorenz 2.0 mm Low Profile Titanium
9. Lorenz 2.0 mm Mini-plate Titanium
10. Anteater Titanium Microdiscectomy System
11. Yasargil Titanium Aneurysm Clips Mini
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
Medicine Products:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...y of Michigan says that it is possible to wish the...nking of a painkiller can trigger the brain to rel...// The study provides the first direct evidence t...icals, called endorphins, play a role in the pheno...
...c test to detect low grade gonadal mosaicism, whic...his test is particularly useful for couples with r...rent miscarriages, and couples over the age of 40 .... During, the process of Invitro fertilization, t...
...th a mutation in the gene BRCA1, which predisposes...y to develop the disease if they lose at least 10 ...archers studied more than 2000 women from five dif...he breast cancer susceptibility genes BRCA1 and BR...
...ng women these days to have their baby delivered a...n for religious regions. The trend may not be all ...// a link between c-section delivery and higher ri...ial attention regarding the newborns' oral health....
Other Medicine News:Health News:Wishing the pain away 2Health News:Watch out those of you planning for a predetermined Cesarean Section 2
(Date:9/4/2008)...trates potent antiviral activity and favorable saf...RIDGE, Mass., Sept. 4 /- Id...pharmaceutical company engaged,in the discovery an...viral,and other infectious diseases, today announc...y evaluating IDX899, a non-nucleoside reverse,tran...
(Date:9/3/2008)...stion Asked. Wrong Children Studied. Wrong,Conclus...ewswire/ -- A Centers for Disease,Control and Prev...no link,between the MMR vaccine and autism. The Na...es nothing to dispel the growing public concern ov...questions concerning design,and methodology., For...
(Date:9/3/2008)...s National Vascular Disease Awareness Month, CHAR...n Pharmaceuticals,LLC, a clinical-stage drug-devel...reatment of unmet medical needs, announced today t...I clinical trial of its lead drug,candidate trans ...T00725881,on the clinicaltrials.gov Website, is in...
(Date:9/3/2008)...ny to Discuss Phase 3 Plans with FDA, PRINCETON, ...Inc.,announced today that it successfully complet...he company,s new, innovative low-dose, once-weekly... by its internal product,code AG-200-15. The Phase...,primary endpoint of ovulation suppression, cycle ...
Breaking Medicine Technology:Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4CDC Misses Target With Flawed MMR/Autism Study 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Patients over age 60 do well after liver transplantation 2645 1Patients over age 60 do well after liver transplantation 2645 2Toy Blocks Might Boost Toddlers Language Skills 2644 1Toy Blocks Might Boost Toddlers Language Skills 2644 2HSN Is Seeing Pink with Susan G Komen for the Cure During National Breast Cancer Awareness Month 2642 1HSN Is Seeing Pink with Susan G Komen for the Cure During National Breast Cancer Awareness Month 2642 2HSN Is Seeing Pink with Susan G Komen for the Cure During National Breast Cancer Awareness Month 2642 3Biomoda President Testifies Before New Mexico Legislature Supporting Clinical Funding for Early Lung Cancer 2640 1Biomoda President Testifies Before New Mexico Legislature Supporting Clinical Funding for Early Lung Cancer 2640 2
...4, 2007 /PRNewswire-FirstCall/ Haemacure,Corporati...mpany,today announced the preliminary findings of...s. , Preliminary findings confirm the presence of ... in significant worldwide,markets, including album...findings take on a strategic significance for Haem...
... 2007 /PRNewswire-FirstCall/ --,Bristol-Myers Squi...fficacy and safety of ORENCIA(R) (abatacept) from ... study in children with juvenile,idiopathic arthri...ne or more disease-modifying anti- rheumatic drugs...rosis factor (TNF) antagonists.,The results demons...
Other Medicine Technology:Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis 2Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis 3Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis 4Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 2Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 3Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 4Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 5Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 6